This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Floyd, E. Articles by Ochoa, R. Search for Related Content PubMed PubMed Citation Articles by Floyd, E. Articles by Ochoa, R. Social Bookmarking                         What's this?

The Trp53 Hemizygous Mouse in Pharmaceutical Development: Points to Consider for Pathologists

Pfizer Nagoya Laboratories, Taketoyo, Aichi, Japan 470-2393, floyd{at}groton.pfizer.com

Peter Mann

Experimental Pathology Laboratories, Inc., Galena, Maryland 21635

Gerald Long

Eli Lilly & Co., Greenfield, Indiana 46140

Ricardo Ochoa

Pfizer Groton Laboratories, Groton, Connecticut 06340

ILSI-HESI sponsored an international consortium for the evaluation of alternative models, including the Trp53+ /- mouse, for use in short-term carcinogenicity testing of pharmaceuticals. Products of the ILSI evaluation included guidance for protocol design and assay interpretation, spontaneous tumor incidences, diagnostic criteria for common proliferative lesions, and results of assays for pharmaceutical agents that are known human and/or rodent carcinogens and non-carcinogens. Based on the ILSI evaluation, recommended protocol elements for this model include: 26-week study duration, groups 15/sex/dose, a positive control group (benzene or p-cresidine), a negative control group and 3 dose groups, the high dose set at MTD or MFD, routine in-life evaluations, and complete necropsies with microscopic evaluation of tissues. Favored statistical analyses are trend tests or pair-wise comparisons, with no adjustments for survival. For an assay to be valid, positive control groups must demonstrate an effect, and the MTD or MFD must be reached in both sexes. Criteria for a negative response include a valid assay, no statistical increase in common tumors, no biologically significant numerical increase in rare tumors, and no tumor incidence above that of historical controls. Positive responses can consist of statistically significant increases in the incidence of a common tumor or numerical increases in a rare tumor, which may not be statistically significant. In either case, the incidence should be clearly above historical control values. Evidence of a dose response or occurrence of hyperplasia in a tissue with a neoplastic response can support interpreting an assay as positive. The two most common spontaneous tumors (>1%) in Trp53+/- mice are malignant thymic lymphomas and subcutaneous sarcomas. Use of implanted electronic transponders can increase the incidence of sarcomas. Important rare spontaneous tumors (incidence 1%) are osteosarcomas and pulmonary adenomas. Many other tumor types have been reported to occur sporadically in Trp53+/- mice. Diagnostic challenges for this model include differentiating lymphoma from atypical thymic hyperplasia and recognizing the variable histopathology of subcutaneous sarcomas. In reported bioassays, Trp53+/- mice responded positively to genotoxic carcinogens, negatively to non-genotoxic rodent carcinogens, and negatively to noncarcinogens, indicating that unlike the 2-year mouse assay, this short-term assay is not overly sensitive. Positive responses often elicited an increase in tumors that occur spontaneously. To successfully use this model, pathologists must understand the biology of the Trp53 tumor suppressor gene and the principles of protocol design and data interpretation for short-term bioassays. They must also know the historical response pattern of Trp53+/- mice to test agents and be able to accurately diagnose tumors in this model. Use of the Trp53+/- mouse presents the pharmaceutical industry with several challenges, one of which is managing the uncertainty created by a lack of precedents for regulatory decisions about some possible outcomes for short-term carcinogenicity assays.

Key Words: p53 • carcinogenicity • cancer • tumor • short-term assay • bioassay • alternative model • genetically modified • knockout.

References

• Bartek J., Lukas J. (2001). Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 490: 117—122.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Blanchard KT, Barthel C., French JE, Holden HE, Moretz R., Pack FD, Tennant RW, Stoll RE (1999). Transponder-induce d sarcoma in the heterozygous p53+/- mouse. Toxicol Pathol 27: 519—527.[Abstract/Free Full Text]
• Boley SE, Anderson EE, French JE, Donehower LA, Walker DB, Recio L. (2000). Loss of p53 in benzene-induced thymic lymphomas in p53+/- mice: Evidence of chromosomal recombination. Cancer Res 60: 2831— 2835.[Abstract/Free Full Text]
• DeGeorge J. (2001). Regulatory Perspective on Application of the Transgenic Alternatives in Pharmaceutical Development. Presented at the annual meeting of the Society of Toxicologic Pathologists, Orlando, FL.
• Donehower LA (1996). The p53-deficient mouse: A model for basic and applied cancer studies. Semin Cancer Biol 7: 269—278.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Donehower LA, Harvey M., Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215—221.[CrossRef][Medline] [Order article via Infotrieve]
• Donehower LA, Harvey M., Vogel H., McArthur MJ, Montgomery CA Jr, Park SH, Thompson T., Ford RJ, Bradley A. (1995). Effects of genetic background on tumorigenesi s in p53-deficient mice. Mol Carcinogen 14: 16—22.[Web of Science][Medline] [Order article via Infotrieve]
• Dunnick JK, Hardisty JF, Herbert RA, Seely JC, Furedi-Machacek EM, Foley JF, Lacks GD, Stasiewicz S., French JE (1997). Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygou s p53-deficient (+/-) mice. Toxicol Pathol 25: 533—540.[Abstract/Free Full Text]
• Eastin WC, Haseman JK, Mahler JF, Bucher JR (1998). The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens. Toxicol Pathol 26: 461—473.[Abstract/Free Full Text]
• French JE (2000). Nature of the Model: the Heterozygous Trp53 Deficient Mouse. Presented at the ILSI HESI Workshop on Evaluation of Alternative Methods for Carcinogenicity Testing, Leesburg, VA.
• French J., Haseman J., Donehower L., Hajian G., LeGrand E., Long G., Ochoa R., Sagartz J., Mixson L., Soper K., Storer R. (2000). The p53+/- Heterozygous Knockout Mouse Model for Short-term Carcinogenicity Testing. ILSI HESI Workshop on Evaluation of Alternative Methods for Carcinogenicity Testing, Leesburg, VA (Abstract #6).
• French JE, Spalding JW, Tennant RW (2000). The p53 Haploinsufficient C57BL/6(N5) Mouse Model and Identification of Mutagenic Chemical Carcinogens. ILSI HESI Workshop on Evaluation of Alternative Methods for Carcinogenicity Testing, Leesburg, VA (Abstract #28).
• . Gulezian D., Jacobson-Ram D., McCullough CB, Olson H., Recio L., Robinson D., Storer R., Tennant R., Ward JM, Neumann DA (2000). Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment. Toxicol Pathol 28: 482—499.[Abstract/Free Full Text]
• Harvey M., McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A., Donehower LA (1993). Spontaneous and carcinogen-induce d tumorigenesis in p53-deficient mice. Nature Genet 5: 225—229.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• International Conference on Harmonisation (1998). Guidance on testing for carcinogenicity of pharmaceuticals. Fed Reg 63: 8983—8986.
• Jacks T., Remington L., Williams BO, Schmitt EM, Halachmi S., Bronson RT, Weinberg RA (1994). Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1—7.[Medline] [Order article via Infotrieve]
• Khanna KK, Jackson SP (2001). DNA double-strand breaks: signaling, repair and the cancer connection. Nature Genet 27: 247—254.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Krueger GR (1990). Lymphoblastic lymphomas, mouse. In: Hematopoietic System, Jones TC, Ward JM, Mohr U, Hunt RD (eds). Springer-Verlag, Berlin, pp 264—275.
• Kuperwasser C., Hurlbut GD, Kittrell FS, Dickinson ES, Laucirica R., Medina D., Naber SP, Jerry DJ (2000). Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni Syndrome. Am J Pathol 157: 2151—2159.[Abstract/Free Full Text]
• Lengauer C., Kinzler KW, Vogelstein B. (1998). Genetic instabilities in human cancers. Nature 396:643—649.[CrossRef][Medline] [Order article via Infotrieve]
• Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323—331.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Long G., Floyd E., McKinney L., Mahler J., Mann P., Montgomery C., Sagartz J., Ward J. ( 1999). The ILSI HESI p53+/- Pathology Review Committee, personal communication.
• Lozano G., Elledge SJ (2000). p53 sends nucleotides to repair DNA. Nature 404: 24—25.[CrossRef][Medline] [Order article via Infotrieve]
• Mahler JF, Flagler ND, Malarkey DE, Mann PC, Haseman JK, Eastin W. (1998). Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. Toxicol Pathol 26: 501— 511.[Abstract/Free Full Text]
• Mitsumori K., Shimo T., Onodera H., Takagi H., Yasuhara K., Tamura T., Aoki Y., Nagata O., Hirose M. (2000). Modifying effects of ethinylestradiol but not methoxychlor on N-ethyl-N-nitrosourea-induce d uterine carcinogenesis in heterozygou s p53-deficient CBA mice. Toxicol Sci 58: 43—49.[Abstract/Free Full Text]
• Moll UM, Zaika A. (2001). Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett 493: 65—69.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rich T., Allen RL, Wyllie AH (2000). Defying death after DNA damage. Nature 407: 777—783.[CrossRef][Medline] [Order article via Infotrieve]
• Sagartz JE, Curtiss SW, Bunch RT, Davila JC, Morris DL, Alden CL (1998). Phenobarbital does not promote hepatic tumorigenesi s in a twenty-six-week bioassay in p53 heterozygou s mice. Toxicol Pathol 26: 492—500.[Abstract/Free Full Text]
• Storer R., Long G., LeGrand E., Sagartz J., Soper K., Ochoa R., French J., Haseman J., Hajian G., Mixson L. (2000). p53+/- Hemizygous Knockout Mouse: Overview of Available Data. Report of the p53 Assay Working Group presented at the ILSI HESI Workshop on Evaluation of Alternative Methods for Carcinogenicity Testing, Leesburg VA.
• Taylor WR, Stark GR (2001). Regulation of the G2/M transition by p53. Oncogene 20: 1803—1825.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Tennant RW (1998). Evaluation and validation issues in the development of transgenic mouse carcinogenicity bioassays. Environ Health Perspect 106 (suppl 2): 473—476.[Medline] [Order article via Infotrieve]
• Tennant RW, Stasiewicz S., Mennear J., French JE, Spalding JW (1999). Genetically altered mouse models for identifying carcinogens. IARC Sci Publ146:123—150.[Medline] [Order article via Infotrieve]
• Torti VR, Cobb AJ, Everitt JI, Marshall MW, Boorman GA, Butterworth BE (2000). A Comparison of Toxicity and Tumorigenesi s in Two Strains of p53 Heterozygous Mice: The Response to Inhaled Bromodichloromethane. ILSI HESI Workshop on Evaluation of Alternative Methods for Carcinogenicity Testing, Leesburg VA. (Abstract #32).
• Venkatachalam S., Shi YP, Jones SN, Vogel H., Bradley A., Pinkel D., Donehower LA (1998). Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation. EMBO J 17: 4657—4667.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Vousden KH (2000). p53: Death star. Cell 103: 691—694.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Zhao R., Gish K., Murphy M., Yin Y., Notterman D., Hoffman WH, Tom E., Mack DH, Levine AJ (2000). Analysis of p53-regulated gene expression patterns using oligonucleiotide arrays. Genes Dev 14: 981—993.[Abstract/Free Full Text]

Toxicologic Pathology, Vol. 30, No. 1, 147-156 (2002)
DOI: 10.1080/01926230252824860


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Morton, K. L. Bailey, C. L. Stout, R. J. Weaver, K. A. White, M. J. Lorenzen, and D. J. Ball N-Methyl-N-Nitrosourea (MNU): A Positive Control Chemical for p53+/- Mouse Carcinogenicity Studies Toxicol Pathol, December 1, 2008; 36(7): 926 - 931. [Abstract] [Full Text] [PDF]

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Floyd, E. Articles by Ochoa, R. Search for Related Content PubMed PubMed Citation Articles by Floyd, E. Articles by Ochoa, R. Social Bookmarking                         What's this?